ACD-101 is under clinical development by Therapeia and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Recurrent Glioblastoma Multiforme (GBM) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ACD-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ACD-101 (131I-ACD-101) is under development for the treatment of glioblastoma multiforme, recurrent glioblastoma multiforme. The drug is administered intravenously. ACD-101 is a phenylalanine derivative that contains an iodine atom. It is a synthetic amino acid. ACD-101 is a radiation sensitizer which increases tumor killing in connection with standard external field radiation therapy (XRT), or intracellular endo-radiation therapy (ERT), using 131I-ACD-101. It acts by targeting DNA and LAT-1 (L-type amino acid transporter).
Therapeia is a developer of diagnostic and therapeutic radiopharmaceuticals for unmet medical needs. The company offers products such as ACD-101, 131I-ACD-101 and 124I-ACD-101. It offers ACD-101 which is administered intravenously over the intact blood brain barrier into tumour tissue and has an anti cancer effect. Therapeia is radio actively labeled with 131I and is used for therapy (131I-ACD-101). The company provides ACD-101 which is also used as a PET tracer for diagnosis (124I-ACD-101), when radiolabelled with 124I. Its products find it’s application in the therapeutic areas of glioma or brain cancer. Therapeia is headquartered in Dresden, Germany.
For a complete picture of ACD-101’s drug-specific PTSR and LoA scores, buy the report here.